PMID- 37303939
OWN - NLM
STAT- MEDLINE
DCOM- 20230613
LR  - 20230613
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 29
IP  - 4
DP  - 2021
TI  - PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via 
      SNHG16/CEBPB/GATA3 axis.
PG  - 275-289
LID - 10.32604/or.2022.03561 [doi]
AB  - Metastasis and paclitaxel (PTX) resistance are the main reason for the poor 
      prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins 
      (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional 
      regulation. The aim of this study was to determine the relationship among RBP, 
      lncRNA and OC and to further guide clinical therapy. Immunohistochemistry 
      revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC 
      chemoresistant tissues and was closely related to advanced (Federation of 
      International of Gynecologists and Obstetricians) FIGO stages and 
      chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in 
      vivo. And the transcripts of small nucleolar RNA host gene SNHG16-L/S were 
      differentially expressed in OC cells and tissues as detected through real-time 
      PCR (RT-PCR). SNHG16-L/S had opposite effects on progression and PTX resistance 
      in OC. Mechanistically, SNHG16-L inhibited GATA-binding protein 3 (GATA3) 
      transcription by binding to CCAAT/enhancer-binding protein B (CEBPB). Moreover, 
      PRPF6 induced the alternative splicing of SNHG16, causing downregulation of 
      SNHG16-L and, leading to the upregulation of GATA3 expression to further promote 
      metastasis and PTX-resistance in OC. Totally, these data unveiled that PRPF6 
      promotes metastasis and PTX resistance of OC through SNHG16-L/CEBPB/GATA3 axis, 
      which provides a new direction for OC treatment.
CI  - (c) 2022 Wang et al.
FAU - Wang, Han
AU  - Wang H
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Zhou, Yingying
AU  - Zhou Y
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Zhang, Siyang
AU  - Zhang S
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Qi, Y A
AU  - Qi YA
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical 
      University, Shenyang, China.
FAU - Wang, Min
AU  - Wang M
AD  - Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical 
      University, Shenyang, China.
LA  - eng
PT  - Journal Article
DEP - 20220831
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (PRPF6 protein, human)
RN  - 0 (RNA Splicing Factors)
RN  - 0 (Transcription Factors)
RN  - 0 (GATA3 protein, human)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (CEBPB protein, human)
RN  - 0 (CCAAT-Enhancer-Binding Protein-beta)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Paclitaxel/pharmacology
MH  - *Ovarian Neoplasms/drug therapy/genetics
MH  - Down-Regulation
MH  - Up-Regulation
MH  - Gynecologists
MH  - RNA Splicing Factors
MH  - Transcription Factors
MH  - GATA3 Transcription Factor/genetics
MH  - CCAAT-Enhancer-Binding Protein-beta
PMC - PMC10208018
OTO - NOTNLM
OT  - GATA3
OT  - Ovarian cancer
OT  - PRPF6
OT  - Paclitaxel resistance
OT  - SNHG16
COIS- The authors declare that they have no conflicts of interest to report regarding 
      the present study.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/13 06:42
PMCR- 2022/08/31
CRDT- 2023/06/12 04:00
PHST- 2022/04/04 00:00 [received]
PHST- 2022/07/13 00:00 [accepted]
PHST- 2023/06/13 06:42 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:00 [entrez]
PHST- 2022/08/31 00:00 [pmc-release]
AID - 3561 [pii]
AID - 10.32604/or.2022.03561 [doi]
PST - epublish
SO  - Oncol Res. 2022 Aug 31;29(4):275-289. doi: 10.32604/or.2022.03561. eCollection 
      2021.